SCHEMBL3307235

SCHEMBL3307235

CC(C)(C)OC(=O)NCc1cccc(CNC=O)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLS O94925 6/20 0.52
KDM4A O75164 1/20 0.46
BRD4 O60885 3/20 0.46
CREBBP Q92793 1/20 0.45
NAMPT P43490 2/20 0.44
ADH1B P00325 1/20 0.44
ADH1C P00326 1/20 0.44
ADH1A P07327 1/20 0.44
ADH7 P40394 1/20 0.44
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA7 P43166 1/20 0.43
CA14 Q9ULX7 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HDAC1 Q13547 1/20 0.42
ATM Q13315 1/20 0.42
CYP3A4 P08684 1/20 0.42
BRD9 Q9H8M2 1/20 0.42
BAZ2B Q9UIF8 1/20 0.42
BAZ2A Q9UIF9 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3307112 0.88 L3MBTL1 (0.52) KDM4ANAMPTADH1BADH1CADH1A
SCHEMBL694491 0.87 GLS (0.56) GLSKDM4ABRD4CREBBPNAMPT
SCHEMBL185365 0.84 ATM (0.55) GLSKDM4ABRD4NAMPTCA12
SCHEMBL30069429 0.84 GLS (0.55) GLSKDM4ABRD4CREBBPNAMPT
SCHEMBL8342682 0.84 GLS (0.55) GLSKDM4ABRD4CREBBPNAMPT
SCHEMBL16181822 0.84 GLS (0.55) GLSKDM4ABRD4CREBBPNAMPT
SCHEMBL13981921 0.84 GLS (0.55) GLSKDM4ABRD4CREBBPNAMPT
SCHEMBL1165088 0.84 GLS (0.55) GLSKDM4ABRD4CREBBPNAMPT
SCHEMBL29952891 0.83 GLS (0.52) GLSKDM4ABRD4CREBBPNAMPT
SCHEMBL209838 0.83 GLS (0.52) GLSKDM4ABRD4CREBBPNAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100099676-A1 SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 SHIONOGI & CO., LTD. (JP) 2010-04-22 US disclosed
EP-2128134-A1 SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 Shionogi&Co., Ltd. (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099676-A1 SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 MMP13, MMP3, MMP26 GLS 143/4885KDM4A 776/4885BRD4 3088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.